DXCM250425C87000
- 0.00
- 0.000.00%
DexCom Newsroom
Wells Fargo Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $98
RBC Capital Maintains DexCom(DXCM.US) With Buy Rating, Cuts Target Price to $100
Wells Fargo Sticks to Its Buy Rating for Dexcom (DXCM)
BTIG Maintains DexCom(DXCM.US) With Buy Rating, Cuts Target Price to $107
BTIG Remains a Buy on Dexcom (DXCM)
Barclays Maintains DexCom(DXCM.US) With Hold Rating, Maintains Target Price $90
Citi Maintains DexCom(DXCM.US) With Buy Rating
Bernstein Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $100
Dexcom's G7 Sensor Approval and Strategic Moves Drive Buy Rating
Wells Fargo Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $98
Barclays Keeps Their Hold Rating on Dexcom (DXCM)
Analysts Offer Insights on Healthcare Companies: Dexcom (DXCM) and Amgen (AMGN)
DexCom Analyst Ratings
Mizuho Initiates DexCom at Outperform With $85 Price Target
Mizuho Securities Initiates DexCom(DXCM.US) With Buy Rating, Announces Target Price $85
Wells Fargo Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $98
Dexcom (DXCM) Receives a Buy From Wells Fargo
Wells Fargo Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $98
TD Cowen Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $100
Analysts Offer Insights on Healthcare Companies: Dexcom (DXCM), Alnylam Pharma (ALNY) and Beta Bionics, Inc. (BBNX)